Home Tags Inotuzumab ozogamicin

Tag: Inotuzumab ozogamicin

Four Ways to Show Nonobviousness of ADC Inventions

As research continues to progress and the scientific community’s appreciation for the power of ADCs has grown, so have the numbers. FDA has now approved at least four ADCs, and hundreds more are in development. The number of patent applications has also grown, with the U.S. Patent and Trademark Office (USPTO) publishing over two hundred patent applications with claims to ADC inventions in the last two years alone.

ADCs – The Dawn of a New Era?

Two decades ago, ADCs were hailed as a major breakthrough, especially in the area of oncology therapeutics. The concept of delivering a potent drug payload directly to the site of the tumor for maximum effect with minimal damage caused to non-cancerous cells was viewed as, if not the Holy Grail of cancer treatment, at least a significant advance towards precision medicine. However, the concept has proved difficult to translate into clinical success.

Antibody-Drug Conjugates at the 59th American Society of Hematology Annual...

This year, in Atlanta, the South's largest and most vibrant city, the 59th annual meeting and exposition of the American Society of Hematology, to...

U.S. FDA Approves Inotuzumab Ozogamicin for Treatment of Patients with R/R...

The United States Food and Drug Administration (FDA) approved inotuzumab ozogamicin (Besponsa™, Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.) for the treatment of...

Antibody-drug Conjugates: Technologies and Global Markets

Less than 3 decades old, antibody-drug conjugate or ADC-technology is a relatively new.  Due to many technological advances, recognition of appropriate target antigens, success...

Inotuzumab ozogamicin Approved in the EU for Adult Patients with Relapsed...

The European Commission has approved inotuzumab ozogamicin (Besponsa®; Pfizer) as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute...

What to Expect at PEGS Boston 2017: A New Pathway of...

From the Charlestown Navy Yard to the Paul Revere House, the Old State House on Washington Street, the New England Aquarium at Central Wharf...

Study Shows High Remission Rate in Leukemia Patients Treated with Inotuzumab...

In an open-label, randomized Phase III INO-VATE ALL study, also known as study 1022, of the investigational drug inotuzumab ozogamicin, also known as CMC-544 (Pfizer), a...

Clinical Updates Confirming Advances and Meaningful Benefits for Patients

Earlier this year, during the meetings of the American Association for Cancer Research (AACR), held April 16-20 in New Orleans, LA, and the Protein...